Hemogenyx Pharmaceuticals (LON:HEMO) Trading Down 2.5% – Here’s Why

Hemogenyx Pharmaceuticals Plc (LON:HEMO)’s share price traded down 2.5% during trading on Tuesday . The company traded as low as GBX 390 ($4.87) and last traded at GBX 395 ($4.93). 2,561 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 11,130 shares. The stock had previously closed at GBX 405 ($5.05).

Hemogenyx Pharmaceuticals Stock Down 2.5 %

The stock has a market cap of £5.29 billion, a PE ratio of -39,500.00 and a beta of 3.14. The company has a debt-to-equity ratio of 92.09, a current ratio of 4.38 and a quick ratio of 6.72. The company has a 50 day moving average price of GBX 138.03 and a two-hundred day moving average price of GBX 49.48.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.